ClinicalTrials.gg
CompletedNCT01017874Updated Jul 8, 2015Results posted

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

A Phase 3 interventional study of Pemetrexed and Cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
42nd of 223
236 · median 64
Started
2009
with 20 others
Phase 3
44 of 227
4 open now
Registered
99th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 42nd largest by enrollment of the 223 interventional ones that give a count, is one of 21 that started in 2009, is one of 44 in phase 3, and was the 99th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants. Half of the participants will receive chemotherapy (pemetrexed/cisplatin) followed by an oral anti-cancer agent (gefitinib) and the other half of the participants will receive only the oral anti-cancer agent (gefitinib).

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of NSCLC with locally advanced or disease that is of non-squamous histology.
  • Participants must be "light ex-smokers" or "never-smokers".

    • "Light ex-smokers" defined as having ceased smoking for greater than or equal to 5 years and not to have exceeded 10 pack-years.
    • "Never-smokers" are defined as having smoked \<100 cigarettes or equivalent during his/her lifetime.
  • Participants must be of East Asian ethnicity.
  • No prior systemic therapy for lung cancer.
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Presence of (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
  • Any evidence of clinically active interstitial lung disease. Asymptomatic participants with chronic, stable, radiographic changes are eligible.
  • Participants whose Epidermal Growth Factor Receptor (EGFR) mutation status is known prior to study entry will be excluded. Participants in which EGFR mutation testing has not been performed, or whose EGFR mutation status is unknown or inconclusive at study entry are eligible.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Cisplatin + Gefitinib

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Gefitinib

  • Active comparator
    Gefitinib

    Drug: Gefitinib

Interventions

  • 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.

    Also known as: Alimta, LY231514

  • 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles

  • 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy

  • 250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date.

    Time frame: Randomization to the first date of measured PD or death up to 37.32 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date).

    Time frame: Randomization up to date of death from any cause up to 57.13 months

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]

    TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions.

    Time frame: Randomization up to 37.52 months

  3. Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]

    DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions.

    Time frame: Randomization up to 37.52 months

  4. Time to Progressive Disease (TtPD)

    TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date.

    Time frame: Randomization to the first date of measured PD up to 37.32 months

  5. Duration of Tumor Response

    The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date.

    Time frame: Date of initial response to the date of measured PD or death up to 34.43 months

  6. Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)

    The LCSS data included participant ratings of 6 symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and 3 summary items (overall symptom severity, interference with daily activities, and overall QoL). Participants recorded their ratings for each item, by placing a mark on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (lower symptom burden, less interference with normal activity, or better QoL) to 100 mm (higher symptom burden, more interference with normal activity, or worse QoL). TWQ was evaluated from date of randomization to first date of worsening, defined as a half standard deviation change as determined from the corresponding baseline item score in the pooled treatment group. For participants not known to have worsened or who were lost to follow-up, TWQ was censored at date of the participant's last LCSS assessment.

    Time frame: Every cycle while on-study therapy and at 3 months post last dose

07

Results

Posted Apr 3, 2014

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin + GefitinibGefitinib
Started118118
Received at least 1 dose of study drug114118
Completed8892
Not completed3026
Withdrew: Withdrawal by subject2320
Withdrew: Sponsor decision31
Withdrew: Lost to follow-up32
Withdrew: Physician decision13

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date.

Time frame:
Randomization to the first date of measured PD or death up to 37.32 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPemetrexed + Cisplatin + GefitinibGefitinib
Progression Free Survival (PFS)8.38 (6.44 to 11.14)9.63 (6.74 to 11.10)
Statistical analysis
  • Pemetrexed + Cisplatin + Gefitinib vs Gefitinib · Wilcoxon (Mann-Whitney) · p = 0.217 · Hazard ratio (hr): 0.85 · 95% CI 0.63 to 1.13
SecondaryOverall Survival (OS)

OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date).

Time frame:
Randomization up to date of death from any cause up to 57.13 months
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed + Cisplatin + GefitinibGefitinib
Overall Survival (OS)26.87 (20.76 to 35.12)27.86 (21.26 to 31.36)
Statistical analysis
  • Pemetrexed + Cisplatin + Gefitinib vs Gefitinib · Wilcoxon (Mann-Whitney) · p = 0.788 · Hazard ratio (hr): 0.94 · 95% CI 0.68 to 1.31
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]

TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions.

Time frame:
Randomization up to 37.52 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
percentage of participantsPemetrexed + Cisplatin + GefitinibGefitinib
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]41.5 (32.5 to 51.0)47.5 (38.2 to 56.9)
SecondaryPercentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]

DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions.

Time frame:
Randomization up to 37.52 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]
percentage of participantsPemetrexed + Cisplatin + GefitinibGefitinib
Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]71.2 (62.1 to 79.2)64.4 (55.1 to 73.0)
SecondaryTime to Progressive Disease (TtPD)

TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date.

Time frame:
Randomization to the first date of measured PD up to 37.32 months
Reported as:
Median · months
Time to Progressive Disease (TtPD)
monthsPemetrexed + Cisplatin + GefitinibGefitinib
Time to Progressive Disease (TtPD)8.61 (6.60 to 11.20)9.69 (6.87 to 11.20)
Statistical analysis
  • Pemetrexed + Cisplatin + Gefitinib vs Gefitinib · Wilcoxon (Mann-Whitney) · p = 0.252 · Hazard ratio (hr): 0.85 · 95% CI 0.63 to 1.14
SecondaryDuration of Tumor Response

The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date.

Time frame:
Date of initial response to the date of measured PD or death up to 34.43 months
Reported as:
Median · months
Duration of Tumor Response
monthsPemetrexed + Cisplatin + GefitinibGefitinib
Duration of Tumor Response12.09 (7.16 to 22.11)11.93 (9.63 to 14.09)
Statistical analysis
  • Pemetrexed + Cisplatin + Gefitinib vs Gefitinib · Wilcoxon (Mann-Whitney) · p = 0.952 · Hazard ratio (hr): 0.84 · 95% CI 0.53 to 1.32
SecondaryTime to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)

The LCSS data included participant ratings of 6 symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and 3 summary items (overall symptom severity, interference with daily activities, and overall QoL). Participants recorded their ratings for each item, by placing a mark on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (lower symptom burden, less interference with normal activity, or better QoL) to 100 mm (higher symptom burden, more interference with normal activity, or worse QoL). TWQ was evaluated from date of randomization to first date of worsening, defined as a half standard deviation change as determined from the corresponding baseline item score in the pooled treatment group. For participants not known to have worsened or who were lost to follow-up, TWQ was censored at date of the participant's last LCSS assessment.

Time frame:
Every cycle while on-study therapy and at 3 months post last dose
Reported as:
Median · months
Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)
monthsPemetrexed + Cisplatin + GefitinibGefitinib
Loss of appetite2.99 (1.71 to 3.68)7.95 (4.90 to NA)
Fatigue4.83 (2.92 to 6.83)7.29 (3.75 to 13.63)
Cough8.57 (5.68 to 10.94)16.69 (6.51 to NA)
Dyspnea6.97 (3.15 to 15.44)18.23 (7.06 to NA)
Hemoptysis19.45 (9.89 to NA)17.05 (10.02 to NA)
Pain6.44 (2.92 to 11.40)15.57 (9.95 to NA)
Overall symptoms4.76 (3.12 to 12.81)13.63 (7.06 to NA)
Interference4.50 (3.02 to 7.03)8.34 (4.90 to NA)
Overall quality of life6.14 (3.52 to 12.78)6.93 (3.22 to 13.63)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin + Gefitinib—35/114 (30.7%)111/114 (97.4%)
Gefitinib—32/118 (27.1%)110/118 (93.2%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventPemetrexed + Cisplatin + GefitinibGefitinib
PneumoniaInfections and infestations7/1149/118
VomitingGastrointestinal disorders4/1140/118
Pleural effusionRespiratory, thoracic and mediastinal disorders0/1144/118
PyrexiaGeneral disorders3/1141/118
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1143/118
DiarrhoeaGastrointestinal disorders2/1142/118
AstheniaGeneral disorders2/1140/118
FatigueGeneral disorders2/1141/118
Septic shockInfections and infestations2/1140/118
Urinary tract infectionInfections and infestations2/1140/118
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPemetrexed + Cisplatin + GefitinibGefitinib
NauseaGastrointestinal disorders70/11426/118
RashSkin and subcutaneous tissue disorders36/11452/118
DiarrhoeaGastrointestinal disorders30/11450/118
Decreased appetiteMetabolism and nutrition disorders43/11429/118
VomitingGastrointestinal disorders41/11413/118
PruritusSkin and subcutaneous tissue disorders34/11438/118
ConstipationGastrointestinal disorders36/11415/118
FatigueGeneral disorders32/11421/118
Alanine aminotransferase increasedInvestigations20/11430/118
CoughRespiratory, thoracic and mediastinal disorders25/11421/118

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Pemetrexed + Cisplatin + GefitinibGefitinibTotal
Mean58.53 ± 10.73059.36 ± 10.67258.95 ± 10.686
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin + GefitinibGefitinibTotal
Female8889177
Male302959
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participant)Pemetrexed + Cisplatin + GefitinibGefitinibTotal
Asian118118236
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin + GefitinibGefitinibTotal
Hong Kong3710
Taiwan392867
Thailand212243
Singapore112
Korea, Republic of5460114
08

Study locations

12 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kowloon, Hong Kong
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Incheon, 405-760, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 110-744, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Singapore, 258499, Singapore
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kuei Shan Hsiang, 33305, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liouying/Tainan, 736, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Puzih City, 613, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 407, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangkok, 10700, Thailand
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiang Mai, 50200, Thailand
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hat Yai, 90110, Thailand
09

References and documents

Publications

  • Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar;11(3):370-9. doi: 10.1016/j.jtho.2015.11.008. Epub 2015 Dec 25. PubMed 26725183 ↗
  • Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K. Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14. PubMed 26511807 ↗
  • Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep;50(13):2219-30. doi: 10.1016/j.ejca.2014.05.011. Epub 2014 Jun 18. PubMed 24953333 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Apr 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2009
First posted
Nov 23, 2009
Start
Nov 2009
Primary completionActual
Apr 2013
CompletionActual
Oct 2014
Results first posted
Apr 3, 2014
Last update
Jul 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01017874
Responsible party
Sponsor
First posted
Nov 23, 2009
Start date
Nov 2009
Primary completion
Apr 2013
Completion
Oct 2014
Results posted
Apr 3, 2014
Last update
Jul 8, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion